Jan. 9, 2012 Acute kidney injury (AKI) has severe consequences, with a 25 to 80 percent risk of in-hospital death. Researchers have found a way to diagnose AKI using a urine test, enabling emergency departments to identify these high-risk patients when they first arrive at the hospital. The study will be published online on January 9, 2012, in the Journal of the American College of Cardiology.
Physicians typically measure a patient's creatinine levels to determine kidney function. But creatinine levels can remain normal for several hours after acute kidney damage, and an accurate assessment requires measurements taken over a period of 1-3 days. This limits their usefulness in an emergency room. Urinary biomarkers, however, require only a half hour or so to obtain a measure of the severity of kidney damage, explains Thomas Nickolas, MD, MS, assistant professor of clinical medicine at Columbia University College of Physicians and Surgeons and a kidney specialist at NewYork-Presbyterian Hospital/The Allen Hospital.
In an international, multi-center study, researchers from Columbia University Medical Center at NewYork-Presbyterian Hospital/The Allen Hospital; Staten Island University Hospital; and Charité-Universitätsmedizin, Max Delbruck Center for Molecular Medicine, and Helios Clinics, Berlin, Germany, took a single measure of five urinary biomarkers from 1,635 emergency room patients upon their admission to the hospital. Although all five biomarkers were elevated in cases of iAKI (intrinsic AKI, the most severe form of AKI), the biomarker called uNGAL was most accurate in the diagnosis of iAKI and best predicted its duration and severity. uNGAL, along with another biomarker, called Kim-1, most accurately predicted death or the need to start dialysis during hospitalization. uNGAL was discovered at NewYork-Presbyterian/Columbia University and at Cincinnati Children's Hospital; it was measured in this study by Abbott's ARCHITECT-NGAL assay, which is available commercially outside the US.
"The ability to identify acute kidney damage while the patient is in triage is especially important in busy urban hospitals, where patients cannot wait for repetitive measures of creatinine and are frequently lost to follow-up," said senior author Jonathan Barasch, MD, PhD, associate professor of medicine and of anatomy and cell biology at Columbia University College of Physicians and Surgeons and a kidney specialist at NewYork-Presbyterian Hospital/The Allen Hospital. "The use of urinary biomarkers could also be of great use to the military, at disaster sites, and in other situations where quick medical decisions must be made."
"Combining urinary biomarkers such as uNGAL with the current standard marker creatinine will significantly improve the identification of patients at risk of death or dialysis in the hospital," added Dr. Kai Schmidt-Ott, MD, a kidney specialist at Charité Berlin, research group leader at the Max Delbrück Center for Molecular Medicine, and adjunct assistant professor at Columbia University Medical Center. "Identifying these patients at the earliest possible time in the emergency room may enable us to introduce new treatment options to improve their outcomes."
The study's authors are Thomas L. Nickolas (CUMC/NYP), Kai M. Schmidt-Ott (Max Delbruck Center for Molecular Medicine) who contributed equally and Pietro Canetta (CUMC/NYP), Catherine Foster (CUMC), Eugenia Singer (Max Delbruck Center for Molecular Medicine), Meghan Sise (CUMC), Antje Elger (Max Delbruck Center for Molecular Medicine), Omar Maarouf (Staten Island University Hospital), David Antonio Sola-Del Valle (CUMC/NYP), Matthew O'Rourke (CUMC/NYP), Evan Sherman (CUMC/NYP), Peter Lee (CUMC), Abdallah Geara (CUMC/NYP), Philip Imus (CUMC/NYP), Achuta Guddati (CUMC), Allison Polland (CUMC), Wasiq Rahman (CUMC), Saban Elitok (Max Delbruck Center for Molecular Medicine), Nasir Malik (CUMC), James Giglio (CUMC/NYP), Suzanne El-Sayegh (Staten Island University Hospital), Prasad Devarajan (Cincinnati Children's Hospital), Sudarshan Hebbar (Abbott Laboratories), Subodh J. Saggi (Staten Island University Hospital), Barry Hahn (Staten Island University Hospital), Ralph Kettritz (Max Delbruck Center for Molecular Medicine), Friedrich C. Luft (Max Delbruck Center for Molecular Medicine), and Jonathan Barasch (CUMC/NYP).
The study was supported by the NIH (DK073462) and the Deutsche Forschungsgemeinschaft.
Other social bookmarking and sharing tools:
Note: If no author is given, the source is cited instead.